drugset
drugset / Trial / NCT01121588

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

NCT01121588 ↗

Phase 1 Terminated 44 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.

Timeline

Start
2011-03-22
Primary completion
2023-09-07
Completion
2023-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Crizotinib Small molecule 250 mg Oral

Indications

cancer